# Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

> **NCT06580223** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 530 (estimated)

## Conditions studied

- Multiple Myeloma
- Venous Thromboembolism

## Interventions

- **DRUG:** Aspirin 100mg
- **DRUG:** Rivaroxaban 10mg

## Key facts

- **NCT ID:** NCT06580223
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 530 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06580223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06580223, "Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06580223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*